(2S)-1-propan-2-ylpyrrolidine-2-carbaldehyde | 1191255-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S)-1-propan-2-ylpyrrolidine-2-carbaldehyde
• CAS: 1191255-77-2
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: XUJWFGWQUZWCBM-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[(1R)-1-aminoethyl]-3-(4-ethoxyphenyl)pyrido[2,3-d]pyrimidin-4-one 、 (2S)-1-propan-2-ylpyrrolidine-2-carbaldehyde 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Optimization of a series of quinazolinone-derived antagonists of CXCR3

  摘要：

  The evaluation of the CXCR3 antagonist AMG 487 in clinic trials was complicated due to the formation of an active metabolite. In this Letter, we will discuss the further optimization of the quinazolinone series that led to the discovery of compounds devoid of the formation of the active metabolite that was seen with AMG 487. In addition, these compounds also feature increased potency and good pharmacokinetic properties. We will also discuss the efficacy of the lead compound 34 in a mouse model of cellular recruitment induced by bleomycin. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.032

文献信息

• Circovirus sequences associated with piglet weight loss disease (PWD)
  申请人：Jestin Andre

  公开号：US20070065457A1

  公开（公告）日：2007-03-22

  The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
• RECOMBINANT MICROORGANISMS AND METHODS OF USE THEREOF
  申请人：LanzaTech New Zealand Limited

  公开号：US20150072395A1

  公开（公告）日：2015-03-12

  The present provides selection markers, methods, nucleic acids, and vectors of use in the preparation of recombinant Clostridium spp.
• GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
  申请人：Novo Nordisk A/S

  公开号：US20150343080A1

  公开（公告）日：2015-12-03

  The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
• US7314628B2
  申请人：——

  公开号：US7314628B2

  公开（公告）日：2008-01-01
• [EN] VAULTS ENGINEERED FOR HYDROPHOBIC DRUG DELIVERY<br/>[FR] VOÛTES CONÇUES POUR L'ADMINISTRATION DE MÉDICAMENT HYDROPHOBE
  申请人：UNIV CALIFORNIA

  公开号：WO2015058025A1

  公开（公告）日：2015-04-23

  The invention relates to compositions of vault complexes for use as delivery agents for hydrophobic and/or aqueous insoluble therapeutic compounds. In one aspect, provided herein is a vault complex comprising a modified major vault protein (MVP), wherein the modified major vault protein comprises a fusion peptide, wherein said fusion peptide is fused to the N-terminus of the major vault protein, and wherein said peptide provides enhanced sequestering of a hydrophobic and/or aqueous insoluble therapeutic compound within the vault complex.